Bill > H5632

This bill requires prescription drug manufacturers to submit a detailed annual list of pharmaceutical sales representatives (drug company employees who market prescription drugs to healthcare providers) to the Department of Business Regulation, with several key provisions. Manufacturers must provide an initial list and update it within 60 days of any changes, pay an annual fee of $55 per sales representative, and submit a comprehensive annual report by March 1st detailing any compensation or gifts over $100 given to healthcare providers and free drug samples distributed. The bill aims to increase transparency in pharmaceutical marketing practices, recognizing that drug companies use sales representatives to influence prescription patterns and potentially drive up healthcare costs. The legislation mandates that only listed sales representatives can market prescription drugs to healthcare providers, and imposes potential civil penalties of up to $10,000 per violation for non-compliance. The Department of Business Regulation will analyze the submitted information and create an annual public report to be shared with state leadership, with the goal of providing insight into pharmaceutical marketing practices and potentially containing healthcare costs. The bill will take effect on January 1, 2026, giving manufacturers time to prepare for the new reporting requirements.

Health and Social Services

https://status.rilegislature.gov/